BlackRock
ZYNE

BlackRock’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

BlackRock’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-740,524
Closed -$241K – 5561
2023
Q2 		$241K Sell
740,524
-98,178
-12% -$35.2K ﹤0.01% 4682
2023
Q1 		$361K Buy
838,702
+2,582
+0.3% +$1.36K ﹤0.01% 4620
2022
Q4 		$443K Buy
836,120
+1,368
+0.2% +$868 ﹤0.01% 4643
2022
Q3 		$611K Sell
834,752
-8,931
-1% -$10.1K ﹤0.01% 4661
2022
Q2 		$962K Buy
843,683
+5,224
+0.6% +$6.65K ﹤0.01% 4546
2022
Q1 		$1.72M Buy
838,459
+2,811
+0.3% +$6.68K ﹤0.01% 4454
2021
Q4 		$2.41M Sell
835,648
-5,505
-0.7% -$20.4K ﹤0.01% 4332
2021
Q3 		$3.57M Buy
841,153
+66,889
+9% +$298K ﹤0.01% 4068
2021
Q2 		$4.1M Buy
774,264
+179,243
+30% +$862K ﹤0.01% 3965
2021
Q1 		$2.77M Buy
595,021
+189,103
+47% +$857K ﹤0.01% 4182
2020
Q4 		$1.34M Buy
405,918
+18,793
+5% +$71.4K ﹤0.01% 4147
2020
Q3 		$1.28M Sell
387,125
-51,518
-12% -$189K ﹤0.01% 4038
2020
Q2 		$1.48M Sell
438,643
-1,069,965
-71% -$5.06M ﹤0.01% 3921
2020
Q1 		$5.78M Sell
1,508,608
-4,997
-0.3% -$23.2K ﹤0.01% 3291
2019
Q4 		$9.14M Buy
1,513,605
+68,824
+5% +$471K ﹤0.01% 3291
2019
Q3 		$10.9M Buy
1,444,781
+132,786
+10% +$1.5M ﹤0.01% 3164
2019
Q2 		$17.8M Buy
1,311,995
+1,014,749
+341% +$11.7M ﹤0.01% 2912
2019
Q1 		$1.61M Sell
297,246
-3,703
-1% -$18K ﹤0.01% 3779
2018
Q4 		$893K Buy
300,949
+2,594
+0.9% +$14.2K ﹤0.01% 3922
2018
Q3 		$2.44M Buy
298,355
+59,998
+25% +$461K ﹤0.01% 3709
2018
Q2 		$2.32M Sell
238,357
-476,828
-67% -$4.89M ﹤0.01% 3684
2018
Q1 		$6.22M Buy
715,185
+36,488
+5% +$393K ﹤0.01% 3344
2017
Q4 		$8.5M Buy
678,697
+7,091
+1% +$81.3K ﹤0.01% 3227
2017
Q3 		$5.61M Buy
671,606
+11,908
+2% +$126K ﹤0.01% 3434
2017
Q2 		$11.2M Buy
659,698
+461,215
+232% +$9.17M ﹤0.01% 3106
2017
Q1 		$3.99M Buy
+198,483
New +$3.94M ﹤0.01% 3452

Other funds holding ZYNE

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock's ZYNE Position: Q3 2023 in Review

BlackRock sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2023, closing a stake of 740,524 shares — an estimated $241K sold.

BlackRock first reported a position in ZYNE in Q1 2017 and held it in 26 quarters. The position peaked at $17.8M in Q2 2019. 43 funds tracked by Wall St. Rank hold ZYNE as of Q3 2023.

  • BlackRock reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
  • BlackRock sold 740,524 Zynerba Pharmaceuticals, Inc shares in Q3 2023, an estimated $241K.
  • BlackRock first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and held it in 26 quarters.
  • BlackRock's Zynerba Pharmaceuticals, Inc position peaked at $17.8M in Q2 2019.
  • 43 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2023.

Based on BlackRock's 13F filing for Q3 2023, filed 13 Nov 2023.